Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Mission Wealth Management LP

Mission Wealth Management LP raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 21.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,910 shares of the biopharmaceutical company's stock after purchasing an additional 2,285 shares during the quarter. Mission Wealth Management LP's holdings in Gilead Sciences were worth $1,447,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Bridgewater Associates LP raised its stake in Gilead Sciences by 122.7% in the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after acquiring an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV increased its holdings in shares of Gilead Sciences by 5.2% in the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after purchasing an additional 14,009 shares during the period. Ontario Teachers Pension Plan Board raised its stake in shares of Gilead Sciences by 54.6% in the fourth quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock worth $3,422,000 after purchasing an additional 13,086 shares during the last quarter. Mufg Securities Americas Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth about $1,699,000. Finally, Convergence Investment Partners LLC boosted its position in Gilead Sciences by 15.8% in the fourth quarter. Convergence Investment Partners LLC now owns 68,447 shares of the biopharmaceutical company's stock valued at $6,322,000 after buying an additional 9,330 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

Several analysts have commented on the stock. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. Bank of America increased their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, JPMorgan Chase & Co. upped their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Trading Up 0.8%

Shares of Gilead Sciences stock opened at $110.83 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $62.69 and a twelve month high of $119.96. The firm's 50-day moving average price is $105.82 and its 200 day moving average price is $102.45. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $137.86 billion, a PE ratio of 299.54, a P/E/G ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business's quarterly revenue was down .3% compared to the same quarter last year. During the same quarter last year, the business posted ($1.32) earnings per share. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.85%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the transaction, the chief executive officer now directly owns 620,268 shares in the company, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares of the company's stock, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold 43,000 shares of company stock valued at $4,630,310 over the last 90 days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.